Propanc Biopharma (OTCMKTS:PPCB) Shares Up 20.6% – Still a Buy?

Propanc Biopharma Inc (OTCMKTS:PPCB) rose 20.6% during mid-day trading on Monday . The stock traded as high as $2.35 and last traded at $2.05. Approximately 297,311 shares were traded during trading, an increase of 148% from the average daily volume of 119,765 shares. The stock had previously closed at $1.70.

Propanc Biopharma Trading Up 20.6%

The firm’s 50-day simple moving average is $0.15 and its 200-day simple moving average is $0.42. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $32.51 million, a PE ratio of -0.16 and a beta of 3.59.

Institutional Trading of Propanc Biopharma

A hedge fund recently bought a new stake in Propanc Biopharma stock. Virtu Financial LLC purchased a new stake in shares of Propanc Biopharma Inc (OTCMKTS:PPCB) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned 0.33% of Propanc Biopharma as of its most recent SEC filing.

About Propanc Biopharma

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.